Targeted Treatment With Alpelisib for Papillary Intralymphatic Angioendothelioma Associated With Somatic PIK3CA Mosaicism
- 23 July 2025
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (10) , e31927
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Primary intraosseous papillary intralymphatic angioendothelioma of the distal femoral epiphysis: a case report with literature reviewSkeletal Radiology, 2024
- Papillary Intralymphatic Angioendothelioma Versus Splenic Lymphatic Malformation With Papillary Endothelial ProliferationAmerican Journal of Surgical Pathology, 2024
- Vascular tumors of intermediate malignancy: An updateHuman Pathology, 2024
- FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth SpectrumClinical Cancer Research, 2023
- Locally Invasive Papillary Intralymphatic Angioendothelioma Arising Within a Lymphatic/Venous MalformationAmerican Journal of Case Reports, 2023
- Splenic Lymphatic Malformation With Papillary Endothelial ProliferationAmerican Journal of Surgical Pathology, 2023
- Papillary Intralymphatic Angioendothelioma in a Child With PIK3CA-Related Overgrowth Spectrum: Implication of PI3K Pathway in the Vascular TumorigenesisPediatric and Developmental Pathology, 2023
- A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestationsOrphanet Journal of Rare Diseases, 2021
- Efficacy of Pegylated Lyposomal Anthracyclines and of Intra-Arterial Carboplatin and Doxorubicin Combined with Local Hyperthermia in a Case of Malignant Endovascular Papillary AngioendotheliomaCurrent Drug Delivery, 2009
- Papillary Intralymphatic Angioendothelioma (PILA)American Journal of Surgical Pathology, 1999